bispecific nanobody

Sanofi's Lunsekimig Just Made the Dupixent Succession Plan Legible

Article: Opinion

Sanofi’s Lunsekimig Just Made the Dupixent Succession Plan Legible

A bispecific nanobody hitting primary endpoints in both asthma and CRSwNP phase 2 trials isn't just a pipeline win...

By Moe Alsumidaie
April 8, 2026

Read More